model leads to frequent rejections. You must correctly specify:

• Study Type: Interventional, Observational, or Expanded Access
• Allocation: Randomized vs Non-Randomized
• Intervention Model: Parallel, Crossover, Factorial, etc.
• Masking: Open Label, Single, Double, Quadruple

Make sure this information matches your protocol. For example, a Phase II randomized placebo-controlled trial should not list “Single Group Assignment.” Reference FDA’s classification standards if unsure.

Error #3: IRB Status and Oversight Inconsistencies

Another frequent issue is IRB approval status mismatches. Sponsors often mark a study as “Recruiting” before receiving ethics approval. This is non-compliant and triggers flags. Ensure that:

• IRB approval is documented before updating the status to “Recruiting”
• Oversight authority is listed correctly (e.g., “United States: FDA”)
• FWA numbers or exemption justifications are available if requested

Incorrect IRB information can delay the public posting of your trial. Review your IRB submission before completing this field.

Error #4: Using Generic or Placeholder Text

Entries like “study drug,” “to be determined,” or “N/A” in critical fields (intervention name, eligibility criteria) are automatic rejections. You must specify:

• Intervention Name: Use the INN (generic) or proprietary name
• Eligibility: Provide inclusion/exclusion criteria in bullet format
• Facilities: Use actual site names and not “TBD”

Placeholder data is only acceptable during drafting. Remove all generic language before submission. Refer to SOPs available at PharmaSOP.in for formatting templates.

Error #5: Failure to Update Recruitment and Site Data

Even after initial submission, many sponsors neglect to update recruitment status, site locations, and contact information. This leads to:

• Outdated public records visible to patients and HCPs
• Noncompliance with FDAAA 801 and 42 CFR Part 11
• Journal editors flagging incomplete registry entries

Set reminders for quarterly reviews of registry data. Update fields such as:

• Recruitment Status – Not yet recruiting, Active, Completed
• Facility Addresses – Including contact emails and PI names
• Start and Completion Dates – Align with protocol amendments if changed

Accurate recruitment data reflects trial credibility and supports patient enrollment efforts.

Error #6: Responsible Party Misidentification

Designating the wrong responsible party is a legal issue. The responsible party must have regulatory authority and either be:

• The Sponsor
• A Principal Investigator (with agreement from sponsor)
• A designated Sponsor-Investigator

Common missteps include assigning administrative staff, CROs without delegated authority, or using generic “study admin” roles. PRS QC will return the record and flag it. Also, ensure the contact email is monitored routinely.

Error #7: Inconsistencies Between Protocol and Registry Data

Discrepancies between your IRB-approved protocol and registry entry invite scrutiny. Ensure consistency in:

• Study Title – Must match the protocol verbatim
• Outcome Measures – Reflect exactly what’s in Section 3 of the protocol
• Eligibility Criteria – Copied as-is from protocol synopsis or appendix

Reviewers compare uploaded documents and PRS entries side-by-side. Use a checklist or delegate to a qualified regulatory coordinator to avoid mismatches. See live protocol-to-registry comparison templates on ClinicalStudies.in.

Error #8: Skipping Validation or Preview Steps

PRS provides a validation tool that checks for formatting issues, missing data, and inconsistency flags. Sponsors often skip this step and submit directly, leading to QC returns. Always:

• Run “Validate” before each major change
• Preview public view to catch formatting errors
• Use “Save and Release” feature with caution—once released, QC review begins immediately

Errors at this stage delay your registry record from being visible and may trigger compliance notices. Regular internal reviews can save hours of QC back-and-forth.

Checklist for Error-Free ClinicalTrials.gov Entry

• ✅ Accurate and complete outcome measures
• ✅ Correct study design elements
• ✅ No placeholder or generic text
• ✅ Matching IRB approval status
• ✅ Updated site and contact information
• ✅ Validated entries using PRS tools

Adopt an internal SOP for registry review and assign responsibilities clearly. This aligns your trial with global transparency mandates and prevents costly delays.

Conclusion

Avoiding common ClinicalTrials.gov entry errors ensures your trial is discoverable, ethically transparent, and legally compliant. By understanding and correcting issues such as mismatched outcomes, incorrect study design fields, and IRB status misreporting, you improve the integrity of your trial record and its readiness for publication or inspection.

For real-time examples and FDA’s enforcement updates, visit FDA.gov or explore registry case studies at PharmaRegulatory.in.